Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

PIK3CA, which encodes the p110α subunit of PI3K, is frequently mutated and oncogenic in breast cancer. PI3Kα inhibitors are in clinical development and despite promising early clinical activity, intrinsic resistance is frequent among patients. We have previously reported that residual downstream mTORC1 activity upon treatment with PI3Kα inhibitors drives resistance to these agents. However, the mechanism underlying this phenotype is not fully understood. Here we show that in cancer cells resistant to PI3Kα inhibition, PDK1 blockade restores sensitivity to these therapies. SGK1, which is activated by PDK1, contributes to the maintenance of residual mTORC1 activity through direct phosphorylation and inhibition of TSC2. Targeting either PDK1 or SGK1 prevents mTORC1 activation, restoring the antitumoral effects of PI3Kα inhibition in resistant cells. Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Citation

Pau Castel, Haley Ellis, Ruzica Bago, Eneda Toska, Pedram Razavi, F Javier Carmona, Srinivasaraghavan Kannan, Chandra S Verma, Maura Dickler, Sarat Chandarlapaty, Edi Brogi, Dario R Alessi, José Baselga, Maurizio Scaltriti. PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition. Cancer cell. 2016 Aug 08;30(2):229-242

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 27451907

View Full Text